Equities research analysts expect that Recro Pharma, Inc. (NASDAQ:REPH) will post $14.90 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $14.62 million and the highest estimate coming in at $15.17 million. Recro Pharma reported sales of $17.28 million in the same quarter last year, which indicates a negative year-over-year growth rate of 13.8%. The business is scheduled to announce its next earnings report on Thursday, August 10th.

On average, analysts expect that Recro Pharma will report full-year sales of $14.90 million for the current financial year, with estimates ranging from $61.40 million to $63.04 million. For the next financial year, analysts anticipate that the company will post sales of $61.19 million per share, with estimates ranging from $58.37 million to $64.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Recro Pharma.

Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.15. The company had revenue of $18.74 million for the quarter, compared to analyst estimates of $15.58 million. Recro Pharma had a negative net margin of 45.15% and a negative return on equity of 61.09%.

A number of equities research analysts have recently commented on REPH shares. Janney Montgomery Scott cut Recro Pharma from a “buy” rating to a “fair value” rating and lowered their target price for the stock from $21.00 to $6.50 in a research note on Wednesday, June 14th. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 target price on the stock in a research note on Wednesday, May 17th. Piper Jaffray Companies set a $11.00 target price on Recro Pharma and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Finally, Roth Capital set a $20.00 target price on Recro Pharma and gave the stock a “buy” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.00.

In related news, major shareholder James E. Flynn sold 10,000 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $6.74, for a total value of $67,400.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James E. Flynn sold 110,447 shares of the business’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $6.39, for a total value of $705,756.33. The disclosure for this sale can be found here. Insiders sold a total of 970,391 shares of company stock worth $7,076,242 over the last 90 days. 21.60% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new position in Recro Pharma during the first quarter worth $150,000. Janney Montgomery Scott LLC raised its position in Recro Pharma by 17.8% in the first quarter. Janney Montgomery Scott LLC now owns 12,485 shares of the specialty pharmaceutical company’s stock worth $109,000 after buying an additional 1,885 shares during the last quarter. Wells Fargo & Company MN raised its position in Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 500 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Recro Pharma during the first quarter worth $156,000. Finally, TFS Capital LLC bought a new position in Recro Pharma during the first quarter worth $827,000. Institutional investors and hedge funds own 64.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Recro Pharma, Inc. (REPH) Will Announce Quarterly Sales of $14.90 Million” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/zacks-brokerages-expect-recro-pharma-inc-reph-will-announce-quarterly-sales-of-14-90-million.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.